

IFU



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Examiner: Unassigned

Yiwen Tang et al.

Serial No. 10/812,780

Art Unit: 1615

Filed: March 29, 2004

Title: Biologically Degradable Compositions for Medical Applications

---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. §§1.97-1.98**

Dear Examiner:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and pursuant to 37 C.F.R. §§1.97-1.98, Applicants hereby notify the U.S. Patent and Trademark Office of the references listed on the attached Form PTO-1449. According to a Notice signed July 11, 2003, the U.S. Patent and Trademark Office has waived the requirement under 37 C.F.R. § 1.98(a)(2)(i) for all patent applications filed after June 30, 2003. *See*, 1276 Off. Gaz. Pat. Office 55. Since this patent application was filed after June 30, 2003, Applicants have not provided copies of the cited U.S. patents or the U.S. Patent Application Publications. Copies of the cited foreign patent documents and other non-patent documents have been submitted herewith.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants reserve the right to dispute the listed documents as prior art during examination. Furthermore, Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application. The submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other material information may exist.


The Examiner is requested to initial the enclosed Form PTO-1449 and return a copy thereof to the undersigned.

The present Information Disclosure Statement is being filed before receiving the first Office Action. Therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required. However, the Commissioner is authorized to charge any deficiencies or other amounts due to Deposit Account No. 07-1850.

Date: July 15, 2004

SQUIRE, SANDERS & DEMPSEY L.L.P.  
One Maritime Plaza, Suite 300  
San Francisco, CA 94111  
Telephone (415) 954-0200  
Facsimile (415) 393-9887

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Mark Lupkowski', written over a horizontal line.

Mark Lupkowski, Ph.D.  
Attorney for Applicants  
Reg. No. 49,010

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	<b>Application Number</b>	10/812,780	
	<b>Filing Date</b>	March 29, 2004	
	<b>First Named Inventor</b>	Yiwen Tang	
	<b>Group Art Unit</b>	1615	
	<b>Examiner Name</b>	Unknown	
<b>Total Number of Pages in This Submission (excluding references)</b>	13	<b>Attorney Docket Number</b>	50623.280

ENCLOSURES (check all that apply)		
<input checked="" type="checkbox"/> Deposit Account 07-1850 Authorization	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input checked="" type="checkbox"/> Postage Paid Return Postcard	<input type="checkbox"/> Drawing(s) In/Formal ___ Sheets with Submission of Drawings Transmittal	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Amendment Transmittal Letter (in duplicate)	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Petition for Extension of Time (___ months) (in duplicate)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input checked="" type="checkbox"/> Information Disclosure Statement (in duplicate) with Form PTO-1449 citing 235 References	<input type="checkbox"/> Terminal Disclaimer	<b>31 Foreign Patent Documents;</b>
<input type="checkbox"/> Express Mail Label No.	<input type="checkbox"/> Request for Refund	<b>21 Other Documents</b>
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	<b>Remarks</b>	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Squire, Sanders & Dempsey L.L.P. Mark Lupkowski, Ph.D., Reg. No. 49,010
Signature	
Date	July 15, 2004

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: July 15, 2004			
Typed or printed name	Dilora Haddad		
Signature		Date	July 15, 2004

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

FORM PTO-1049 (Modified)

US DEPARTMENT OF

Docket No.

50623.280

Application No.

10/812,780

COMMERCE

For use through 10/31/2002

US Patent and Trademark Office

# **INFORMATION DISCLOSURE CITATION** **in an Application**

(Use several sheets if necessary)

Applicant

Yiwen Tang et al.

Filing Date

March 29, 2004

Group Art Unit

1615

## **U.S. PATENT DOCUMENTS**

Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
/A.F./	A1	3,839,743	10/8/74	Schwarcz	3	1	
	A2	3,900,632	8/19/75	Robinson	428	196	
	A3	4,110,497	8/29/78	Hoel	428	190	
	A4	4,321,711	3/30/82	Mano	3	1.4	
	A5	4,346,028	8/24/82	Griffith	524	417	
	A6	4,633,873	1/6/87	Dumican et al.	128	334	
	A7	4,656,083	4/7/87	Hoffman et al.	428	265	
	A8	4,718,907	1/12/88	Karwoski et al.	623	12	
	A9	4,722,335	2/2/88	Vilasi	128	207.14	
	A10	4,723,549	2/9/88	Wholey et al.	128	344	
	A11	4,732,152	3/22/88	Wallstén et al.	128	343	
	A12	4,733,665	3/29/88	Palmaz	128	343	
	A13	4,739,762	4/26/88	Palmaz	128	343	
	A14	4,740,207	4/26/88	Kreamer	623	1	
	A15	4,743,252	5/10/88	Martin, Jr. et al.	623	1	
	A16	4,768,507	9/6/88	Fischell et al.	128	303	
	A17	4,776,337	10/11/88	Palmaz	128	343	
	A18	4,816,339	3/28/89	Tu et al.	428	421	
	A19	4,850,999	7/25/89	Planck	623	1	
	A20	4,877,030	10/31/89	Beck et al.	128	343	
	A21	4,878,906	11/7/89	Lindemann et al.	623	1	
	A22	4,879,135	11/7/89	Greco et al.	427	2	
	A23	4,902,289	2/20/90	Yannas	623	1	
	A24	4,977,901	12/18/90	Ofstead	128	772	
✓	A25	4,994,298	2/19/91	Yasuda	427	41	
/A.F./	A26	5,019,090	5/28/91	Pinchuk	606	194	

/A.F./	A27	5,028,597	7/2/91	Kodama et al.	514	56	
	A28	5,059,211	10/22/91	Stack et al.	606	198	
	A29	5,062,829	11/5/91	Pryor et al.	604	57	
	A30	5,084,065	1/28/92	Weldon et al.	623	1	
	A31	5,085,629	2/4/92	Goldberg et al.	604	8	
	A32	5,100,429	3/31/92	Sinofsky et al.	606	195	
	A33	5,108,755	4/28/92	Daniels et al.	424	426	
	A34	5,112,457	5/12/92	Marchant	204	165	
	A35	5,123,917	6/23/92	Lee	623	1	
	A36	5,156,623	10/20/92	Hakamatsuka et al.	623	11	
	A37	5,163,951	11/17/92	Pinchuk et al.	623	1	
	A38	5,163,952	11/17/92	Froix	623	1	
	A39	5,163,958	11/17/92	Pinchuk	623	11	
	A40	5,167,614	12/1/92	Tessmann et al.	604	8	
	A41	5,192,311	3/9/93	King et al.	623	1	
	A42	5,197,977	3/30/93	Hoffman, Jr. et al.	623	1	
	A43	5,234,456	8/10/93	Silvestrini	606	194	
	A44	5,234,457	8/10/93	Andersen	606	198	
	A45	5,236,447	8/17/93	Kubo et al.	623	1	
	A46	5,279,594	1/18/94	Jackson	604	265	
	A47	5,282,860	2/1/94	Matsuno et al.	623	12	
	A48	5,289,831	3/1/94	Bosley	128	899	
	A49	5,290,271	3/1/94	Jernberg	604	891.1	
	A50	5,306,286	4/26/94	Stack et al.	606	198	
	A51	5,306,294	4/26/94	Winston et al.	623	1	
	A52	5,328,471	7/12/94	Slepian	604	101	
	A53	5,330,500	7/19/94	Song	606	198	
	A54	5,342,348	8/30/94	Kaplan	604	891.1	
	A55	5,342,395	8/30/94	Jarrett et al.	606	219	
	A56	5,342,621	8/30/94	Eury	424	423	
	A57	5,356,433	10/18/94	Rowland et al.	623	11	
↓	A58	5,383,925	1/24/95	Schmitt	623	1	
/A.F./	A59	5,385,580	1/31/95	Schmitt	623	1	

/A.F./	A60	5,389,106	2/14/95	Tower	606	198	
	A61	5,441,515	8/15/95	Khosravi et al.	606	194	
	A62	5,443,458	8/22/95	Eury	604	891.1	
	A63	5,455,040	10/3/95	Marchant	424	426	
	A64	5,464,650	11/7/95	Berg et al.	427	2.30	
	A65	5,502,158	3/26/96	Sinclair et al.	528	354	
	A66	5,514,379	5/7/96	Weissleder et al.	424	426	
	A67	5,527,337	6/18/96	Stack et al.	606	198	
	A68	5,554,120	9/10/96	Chen et al.	604	96	
	A69	5,556,413	9/17/96	Lam	606	198	
	A70	5,578,046	11/26/96	Liu et al.	606	151	
	A71	5,578,073	11/26/96	Haimovich et al.	623	1	
	A72	5,591,607	1/7/97	Gryaznov et al.	435	91.1	
	A73	5,593,403	1/14/97	Buscemi	606	2	
	A74	5,593,434	1/14/97	Williams	623	1	
	A75	5,599,301	2/4/97	Jacobs et al.	604	65	
	A76	5,599,922	2/4/97	Gryaznov et al.	536	25.3	
	A77	5,605,696	2/25/97	Eury et al.	424	423	
	A78	5,629,077	5/13/97	Turnlund et al.	442	38	
	A79	5,631,135	5/20/97	Gryaznov et al.	435	6	
	A80	5,637,113	6/10/97	Tartaglia et al.	623	1	
	A81	5,667,767	9/16/97	Greff et al.	424	9.411	
	A82	5,670,558	9/23/97	Onishi et al.	523	112	
	A83	5,693,085	12/2/97	Buirge et al.	623	1	
	A84	5,700,286	12/23/97	Tartaglia et al.	623	1	
	A85	5,707,385	1/13/98	Williams	606	192	
	A86	5,716,981	2/10/98	Hunter et al.	514	449	
	A87	5,726,297	3/10/98	Gryaznov et al.	536	22.1	
	A88	5,725,549	3/10/98	Lam	606	198	
	A89	5,728,751	3/17/98	Patnaik	523	112	
	A90	5,733,925	3/31/98	Kunz et al.	514	449	
↓	A91	5,741,881	4/21/98	Patnaik	528	75	
/A.F./	A92	5,756,457	5/26/98	Wang et al.	514	12	

/A.F./	A93	5,756,476	5/26/98	Epstein et al.	514	44	
	A94	5,766,710	6/16/98	Turnlund et al.	428	36.1	
	A95	5,800,516	9/1/98	Fine et al.	623	1	
	A96	5,811,447	9/22/98	Kunz et al.	514	411	
	A97	5,824,049	10/20/98	Ragheb et al.	623	1	
	A98	B1 4,739,762	10/27/98	Palmaz (Reexamination Certificate)	606	108	
	A99	5,830,178	11/3/98	Jones et al.	604	49	
	A100	5,830,461	11/3/98	Billiar	424	94.4	
	A101	5,830,879	11/3/98	Isner	514	44	
	A102	5,833,651	11/10/98	Donovan et al.	604	53	
	A103	5,834,582	11/10/98	Sinclair et al.	528	354	
	A104	5,837,313	11/17/98	Ding et al.	427	2.21	
	A105	5,837,835	11/17/98	Gryaznov et al.	536	23.1	
	A106	5,851,508	12/22/98	Greff et al.	424	9.411	
	A107	5,854,207	12/29/98	Lee et al.	514	2	
	A108	5,855,618	1/5/99	Patnaik et al.	623	11	
	A109	5,858,746	1/12/99	Hubbell et al.	435	177	
	A110	5,865,814	2/2/99	Tuch	604	265	
	A111	5,873,904	2/23/99	Ragheb et al.	623	1	
	A112	5,874,165	2/23/99	Drumheller	428	308.4	
	A113	5,876,743	3/2/99	Ibsen et al.	424	426	
	A114	5,877,263	3/2/99	Patnaik et al.	525	453	
	A115	5,879,713	3/9/99	Roth et al.	424	489	
	A116	5,891,192	4/6/99	Murayama et al.	623	1	
	A117	5,897,955	4/27/99	Drumheller	428	422	
	A118	5,914,182	6/22/99	Drumheller	428	308.4	
	A119	5,916,870	6/29/99	Lee et al.	514	2	
	A120	5,942,209	8/24/99	Leavitt et al.	424	1.25	
	A121	5,948,428	9/7/99	Lee et al.	424	426	
	A122	5,957,975	9/28/99	Lafont et al.	623	1	
	A123	5,965,720	10/12/99	Gryaznov et al.	536	23.1	
↓	A124	5,971,954	10/26/99	Conway et al.	604	96	
/A.F./	A125	5,980,564	11/9/99	Stinson	623	1	

/A.F./	A126	5,980,928	11/9/99	Terry	424	427	
	A127	5,980,972	11/9/99	Ding	427	2.24	
	A128	5,981,568	11/9/99	Kunz et al.	514	411	
	A129	5,997,468	12/7/99	Wolff et al.	600	36	
	A130	6,015,541	1/18/00	Greff et al.	424	1.25	
	A131	6,042,875	3/28/00	Ding et al.	427	2.24	
	A132	6,048,964	4/11/00	Lee et al.	530	350	
	A133	6,051,648	4/18/00	Rhee et al.	525	54.1	
	A134	6,056,993	5/2/00	Leidner et al.	427	2.25	
	A135	6,060,451	5/9/00	DiMaio et al.	514	13	
	A136	6,071,266	6/6/00	Kelley	604	265	
	A137	6,074,659	6/13/00	Kunz et al.	424	423	
	A138	6,080,177	6/27/00	Igaki et al.	606	198	
	A139	6,080,488	6/27/00	Hostettler et al.	428	423.3	
	A140	6,093,463	7/25/00	Thakrar	428	36.9	
	A141	6,096,070	8/1/00	Ragheb et al.	623	1	
	A142	6,096,525	8/1/00	Patnaik	435	181	
	A143	6,099,562	8/8/00	Ding et al.	623	1.46	
	A144	6,103,230	8/15/00	Billiar et al.	424	94.4	
	A145	6,107,416	8/22/00	Patnaik et al.	525	453	
	A146	6,110,188	8/29/00	Narciso, Jr.	606	153	
	A147	6,113,629	9/5/00	Ken	623	1.1	
	A148	6,117,979	9/12/00	Hendriks et al.	530	356	
	A149	6,120,536	9/19/00	Ding et al.	623	1.43	
	A150	6,120,904	9/19/00	Hostettler et al.	428	423.3	
	A151	6,121,027	9/19/00	Clapper et al.	435	180	
	A152	6,127,173	10/3/00	Eckstein et al.	435	320.1	
	A153	6,129,761	10/10/00	Hubbell	623	11	
	A154	6,153,252	11/28/00	Hossainy et al.	427	2.3	
	A155	B1 4,776,337	12/5/00	Palmaz (Reexamination Certificate)	606	108	
	A156	6,159,951	12/12/00	Karpeisky et al.	514	45	
↓	A157	6,165,212	12/26/00	Dereume et al.	623	1.13	
/A.F./	A158	6,166,130	12/26/00	Rhee et al.	525	54.1	



/A.F./	A159	6,169,170	1/2/01	Gryaznov et al.	536	23.1	
	A160	6,171,609	1/9/01	Kunz	424	422	
	A161	6,174,330	1/16/01	Stinson	623	1.34	
	A162	6,177,523	1/23/01	Reich et al.	525	459	
	A163	6,224,626	5/1/01	Steinke	623	1.16	
	A164	6,228,845	5/8/01	Donovan et al.	514	44	
	A165	6,240,616	6/5/01	Yan	29	527.2	
	A166	6,245,103	6/12/01	Stinson	623	1.22	
	A167	6,251,135	6/26/01	Stinson et al.	623	1.34	
	A168	6,251,142	6/26/01	Bernacca et al.	623	23.57	
	A169	6,287,332	9/11/01	Bolz et al.	623	1.15	
	A170	6,423,092	7/23/02	Datta et al.	623	1.15	
	A171	6,527,801	3/4/03	Dutta	623	1.46	
	A172	6,626,939	9/30/03	Burnside et al.	623	1.38	
	A173	6,656,162	12/2/03	Santini, Jr. et al.	604	191	
	A174	6,746,773	6/8/04	Llanos et al.	428	421	
	A175	6,752,826	6/22/04	Holloway et al.	623	1.13	
	A176	4,733,665 C2	1/29/02	Palmaz (Reexamination Certificate)	606	108	
	A177	2002/0002399	1/3/02	Huxel et al.	623	1.15	
	A178	2002/0004060	1/10/02	Heublein et al.	424	422	
	A179	2002/0004101	1/10/02	Ding et al.	427	261	
	A180	2002/0116050	8/22/02	Kocur	623	1.15	
	A181	2003/0105518	6/5/03	Dutta	623	1.38	
↓	A182	2003/0100865	5/29/03	Santini, Jr. et al.	604	161	
/A.F./	A183	2004/0098095	5/20/04	Burnside et al.	623	1.13	

### FOREIGN PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No
/A.F./	B1	EP 0 108 171	5/16/84	European				
↓	B2	EP 0 144 534	6/19/85	European				
	B3	WO 89/03232	4/20/89	PCT				
	B4	WO 90/01969	3/8/90	PCT				
↓	B5	EP 0 364 787	4/25/90	European				
/A.F./	B6	WO 90/04982	5/17/90	PCT				

/A.F./	B7	WO 90/06094	6/14/90	PCT				
	B8	EP 0 397 500	11/14/90	European				
	B9	WO 91/17744	11/28/91	PCT				
	B10	WO 91/17789	11/28/91	PCT				
	B11	EP 0 464 755	1/8/92	European				
	B12	GB 2 247 696	3/11/92	Great Britain				
	B13	WO 92/10218	6/25/92	PCT				
	B14	EP 0 493 788	7/8/92	European				
↓	B15	WO 93/06792	4/15/93	PCT				
/A.F./	B16	EP 0 554 082	8/4/93	European				
	B17	EP 0 578 998	1/19/94	European			X	
/A.F./	B18	EP 0 604 022	6/29/94	European				
	B19	DE 44 07 079	9/29/94	German			X	
	B20	WO 94/21196	9/29/94	PCT				
	B21	EP 0 621 017	10/26/94	European				
	B22	EP 0 623 354	11/9/94	European				
	B23	EP 0 665 023	8/2/95	European				
	B24	WO 95/29647	11/9/95	PCT				
	B25	DE 197 31 021	1/21/99	German			X	
	B26	DE 198 56 983	12/30/99	German			X	
	B27	EP 0 970 711	1/12/00	European			X	
	B28	WO 00/12147	3/9/00	PCT				
	B29	WO 00/64506	11/2/00	PCT				
↓	B30	WO 01/01890	1/11/01	PCT				
/A.F./	B31	WO 2004/023985	3/25/04	PCT				

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, etc.)

/A.F./	C1	Ansari, <i>Tubal Reanastomosis Using Absorbable Stent</i> , International Journal of Fertility, Vol. 23, No. 1 (1978).
	C2	Ansari, <i>End-to-end tubal anastomosis using an absorbable stent</i> , Fertility and Sterility, Vol. 32(2), pp. 197-201 (August 1979).
	C3	Bull, <i>Parylene Coating for Medical Applications</i> , Medical Product Manufacturing News (March 1993).
↓	C4	Casper et al., <i>Fiber-Reinforced Absorbable Composite for Orthopedic Surgery</i> , Polymeric Materials Science and Engineering, 53:497-501 (1985).
/A.F./	C5	Detweiler et al., <i>Sutureless Anastomosis of the Small Intestine and the Colon in Pigs Using an Absorbable Intraluminal Stent and Fibrin Glue</i> , Journal of Investigative Surgery, Vol. 8(2), pp. 129-140 (March 1995).

/A.F./	C6	Detweiler et al., <i>Sutureless Cholecystojejunostomy in Pigs Using an Absorbable Intraluminal Stent and Fibrin Glue</i> , Journal of Investigative Surgery, Vol. 9(1), pp. 13-26 (Jan./Feb. 1996).
	C7	Detweiler et al., <i>Sliding, Absorbable, Reinforced Ring and an Axially Driven Stent Placement Device for Sutureless Fibrin Glue Gastrointestinal Anastomosis</i> , Journal of Investigative Surgery, Vol. 9(6), pp. 495-504 (Nov./Dec. 1996).
	C8	Detweiler et al., <i>Gastrointestinal Sutureless Anastomosis Using Fibrin Glue: Reinforcement of the Sliding Absorbable Intraluminal Nontoxic Stent and Development of a Stent Placement Device</i> , Journal of Investigative Surgery, Vol. 9(2), pp. 111-130 (Mar./Apr. 1996).
	C9	Devanathan et al., <i>Polymeric Conformal Coatings for Implantable Electronic Devices</i> , IEEE Transactions on Biomedical Engineering, Vol. BME-27(11):671-675 (1980).
	C10	Feng-Chun et al., <i>Assessment of Tissue Blood Flow Following Small Artery Welding with an Intraluminal Dissolvable Stent</i> , Microsurgery, Vol. 19(3), pp. 148-152 (1999).
	C11	Hahn et al., <i>Biocompatibility of Glow-Discharge-Polymerized Films and Vacuum-Deposited Parylene</i> , J Applied Polymer Sci, 38:55-64 (1984).
	C12	Hahn et al., <i>Glow Discharge Polymers as Coatings for Implanted Devices</i> , ISA, pp. 109-111 (1981).
	C13	Kelley et al., <i>Totally Resorbable High-Strength Composite Material</i> , Advances in Biomedical Polymers, 35:75-85 (1987).
	C14	Kubies et al., <i>Microdomain Structure In Polylactide-block-poly(ethylene oxide) Copolymer Films</i> , Biomaterials 21:529-536 (2000).
	C15	Kutryk et al., <i>Coronary Stenting: Current Perspectives</i> , companion to the Handbook of Coronary Stents (1999).
	C16	Muller et al., <i>Advances in Coronary Angioplasty: Endovascular Stents</i> , Coron Arter Dis, 1(4):438-448 (Jul/Aug. 1990).
	C17	Nichols et al., <i>Electrical Insulation of Implantable Devices by Composite Polymer Coatings</i> , ISA Transactions, 26(4):15-18 (1987).
	C18	Redman, <i>Clinical Experience with Vasovasostomy Utilizing Absorbable Intravasal Stent</i> , Urology, Vol. 20(1), pp. 59-61 (July 1982).
	C19	Rust et al., <i>The Effects of Absorbable Stenting on Postoperative Stenosis of the Surgically Enlarged Maxillary Sinus Ostia in a Rabbit Animal Model</i> , Archives of Otolaryngology, Vol. 122(12), pp. 1395-1397 (December 1996).
✓	C20	Schatz, <i>A View of Vascular Stents</i> , Circulation, 79(2):445-457 (Feb. 1989).
/A.F./	C21	Schmidt et al., <i>Long-Term Implants of Parylene-C Coated Microelectrodes</i> , Med & Biol Eng & Comp, 26(1):96-101 (Jan. 1988).
EXAMINER	/Abigail Fisher/	
	DATE CONSIDERED	10/09/2007
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		